Condition: Advanced Solid Tumors Harboring KRAS G12C Mutation · Sponsor: Bayer
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells from growing and can lead to their death. Sotorasib is already approved to be used by doctors. However, when sotorasib works, it normally only works for a period of time, after which the cancer starts to grow again, and the patient may need a different treatment. BAY3498264 is a drug that is currently under development. It is expected to prevent the activity of a protein called son of sevenless 1 (SOS1). The SOS1 protein works together with KRAS; by blocking the activity of SOS1 with BAY3498264, it is hoped that the benefit offered by treatment with sotorasib may be increased - for example, resulting in a longer or deeper response. The main purpose of this first-in-human study is to learn how safe BAY3498264 is when given together with sotorasib and what is the maximum dose of BAY3498264 that can be safely given to participants together with sotorasib. During the study, participants will receive the following treatments: * BAY3498264: participants will first receive BAY3498264 alone for seven days and then BAY3498264 in combination with sotorasib. These combination treatments will be given in cycles, each lasting 21 days. * Sotorasib: participants will receive a standard, approved dose of Sotorasib once every day with BAY3498264. The treatment …
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| Border Medical oncology - Albury Wodonga Regional Cancer Centre | Albury, New South Wales, Australia | Recruiting |
| Macquarie University Hospital - Oncology Department | Macquarie Park, New South Wales, Australia | Recruiting |
| Peninsula and Southeast Oncology | Frankston, Victoria, Australia | Recruiting |
| Rigshospitalet Copenhagen University Hospital | Oncology Department | Copenhagen, Capital Region, Denmark | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica | Rome, Lazio, Italy | Recruiting |
| Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia | Rozzano, Italy | Recruiting |
| Institut Catala D'oncologia | Hospitalet | Oncologia | L'Hospitalet de Llobregat, Barcelona, Spain | Recruiting |
| Hospital Universitari Vall D Hebron | Oncologia | Barcelona, Spain | Not Yet Recruiting |
| The Christie NHS Foundation Trust - Christie Hospital | Manchester, Greater Manchester, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton | Sutton, Surrey, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06659341